Decheng Capital — 2018 Investments

3 investments dated 2018 · listed companies and verified rows first · show all

Grailgrail.com in 𝕏NASDAQ: GRALMay 2018

GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesMenlo Park, US

Jeffrey T. Huber(Director)Joshua Ofman, MD, MSHS(Chief Executive Officer)inAaron Freidin(Executive Officer)inRobert Ragusa(Executive Officer, Director)Jennifer Cook(Executive Officer, Director)inRichard Klausner(Director)

Board seatMin Cui· per SEC Form D

Co-investorsAmino Capital ARCH Venture Partners Bezos Expeditions Bluebird Ventures Dentsu Ventures Felicis Ventures +13 more

Aadi Bioscienceaadibio.com inNASDAQ: WHWKMay 2018 · $23M

Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition.

BiotechHealthtechMorristown, US

Scott Giacobello(Executive Officer)inBryan Ball(Executive Officer)Dave Lennon(Executive Officer, Director)inDavid Dornan(Executive Officer)James Murphy(Executive Officer)Stephen Pakola(Executive Officer)

Co-investors3B Future Health Fund Ally Bridge Group Vivo Capital OrbiMed

Apexigenapexigen.comAug 2018 · $73M

BiotechSan Carlos, US

Xiaodong Yang(President, CEO and Secretary)inOvid Trifan(Executive Officer)Amy Wong(Executive Officer)Francis Sarena(Chief Operating Officer)Frank Hsu(Chief Medical Officer)William Duke, Jr.(Chief Financial Officer)

Co-investorsEFung Capital ShangBay Capital LLC SVE Capital 3E Bioventures Capital Sv Tech Ventures, Inc.Virtus Inspire Ventures

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.